As high expression levels of ATF3 are a feature of QCCs that promotes resistance to anticancer reagents in CRC cells, we asked whether lowering ATF3 could improve the efficacy of drugs targeting the proliferating cancer cells. This evidence concerns the gene ATF3 and colorectal carcinoma.